Amersham Biosciences and GeneBio Expand Alliance to Develop Next Generation Proteomics Image Analysis Software
July 16, 2003 – Amersham Biosciences, the life sciences business of Amersham (LSE:, NYSE:, OSE: AHM) and Geneva Bioinformatics (GeneBio) S.A. have signed an exclusive agreement to provide researchers with the next generation of 2-D gel image analysis tools for proteomics research.
This collaboration between Amersham Biosciences and GeneBio will entail the complete integration of the Melanie 2-D Gel Analysis Software, developed by the Swiss Institute of Bioinformatics (SIB), into the ImageMaster image analysis software platform from Amersham Biosciences.
The new version of ImageMaster, incorporating Melanie, will help to address the current critical bottlenecks of image analysis in proteomics research, by enhancing the speed and accuracy of the software and generating statistically accurate and pertinent results. This integrated 2-D image analysis software will be available from Amersham Biosciences with the new release of ImageMaster.
Nasri Nahas, C.E.O. of GeneBio, said “The integration of Melanie into the ImageMaster platform is an exciting opportunity for GeneBio and the SIB to continue our active participation in the development and evolution of the next generation in 2-D image analysis software. We believe that this collaboration with Amersham Biosciences will permit us to jointly define further developments and opportunities in this arena.”
Under the agreement, future imaging software will be collaboratively developed utilizing the strengths of Amersham Biosciences, GeneBio, the SIB and the Melanie backbone. Alan Livingston, Marketing Director of Proteomics at Amersham Biosciences commented: “This partnership demonstrates both companies’ commitment to the field of 2-D image analysis and will enable Amersham Biosciences to build on the tremendous expertise GeneBio and the SIB have in the proteomics application area, and especially in proteomics analysis software and databases. The new version of ImageMaster will enable proteomics researchers to generate high quality biological data quickly and reliably.”
This agreement expands the strategic alliance between the two companies signed in January 2003 to develop and distribute novel proteomics analysis software, databases and training tools.
Amersham Biosciences, the life sciences business of Amersham plc (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences’ products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia.
Founded in 1997, Geneva Bioinformatics (GeneBio) S.A. has evolved from its initial, and continuing, mandate as exclusive distributor for the renowned Swiss Institute of Bioinformatics (SIB) and emerged as a multifaceted Bioinformatics company. Through both in-house development and strategic alliances with key research institutions and companies GeneBio offers its clients original, knowledge-oriented discovery tools and solutions to further enhance proteomics-based research. For more information about GeneBio, please visit: www.genebio.com
Amersham Biosciences—enabling molecular medicine
Press Contact
Helen Petts
Product PR Manager
T – +44 (0) 1494 498 068
helen.petts@amersham.com
